MedTrace Logo

Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function

NCT01392807 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2014-10-15

No results posted yet for this study

Summary

The purpose of this study is to assess the pharmacokinetics of NKTR-118 in patients with impaired hepatic function versus subjects with normal hepatic function.

Conditions

  • Hepatic; Functional Disturbance

Interventions

DRUG

NKTR-118

25 mg Oral tablets, single dose

Sponsors & Collaborators

Principal Investigators

  • Mark Sostek, MD · AstraZeneca

  • Thomas Marbury, MD · Orlando Clinical Research Center

  • Bo Fransson, MD · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01392807 on ClinicalTrials.gov